Product Quality Lifecycle Implementation - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Product Quality Lifecycle Implementation
The authors provide an overview of the new ISPE Guide Series on Product Quality Lifecycle Implementation and how the guides can be used in a complementary way with existing guidance from FDA and the International Conference on Harmonization.

Pharmaceutical Technology
Volume 36, Issue 4, pp. 120-127


In response to ICH and regulatory guidelines, a group of experts representing the industry who have successfully prosecuted enhanced, QbD approaches to development and manufacture of drug substances and drug products have produced for ISPE two parts of a guide series on product realization. These guides can serve as learning material for practitioners and be a reference of relevant information.

Bruce S. Davis is a principal, Global Consulting; Ranjit R. Deshmukh, PhD, is senior director of Corporate Technical Science, MedImmune; John V. Lepore, PhD, is senior director, Chemical Process Development and Commercialization, Merck & Co Inc.; Line Lundsberg-Nielsen, PhD, is a senior consultant, NNE Pharmaplan; Roger Nosal is vice-president, Global Chemistry, Manufacturing & Controls, Pfizer, Inc.; Stephen M. Tyler is director, Analytics and Technical Projects, Abbott Laboratories; and Christopher Potter, PhD*, is a CMC Pharmaceutical Consultant.

*To whom all correspondence should be addressed.

Note: The ISPE Guide series is available at


1. ICH, Q8(R2) Pharmaceutical Development (August 2009).

2. ICH, Q9 Quality Risk Management (November 2005).

3. ICH, Q10 Pharmaceutical Quality System (June 2008).

4. FDA, Guidance for Industry: Pharmaceutical cGMPs for the 21st Century—A Risk-Based Approach (September 2004).

5. FDA, Guidance for Industry: PAT–A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (September 2004).

6. FDA, Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations (September 2006).

7. FDA, Guidance for Industry: Process Validation: General Principles and Practices (January 2011).

8. ICH, Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities), Step 2 (May 2011).

9. ICH, Q8, Q9, and Q10 Questions and Answers, Rev. 4 (November 2011).

10. ICH Quality Implementation Working Group, Points to Consider, ICH-Endorsed Guide for ICH Q8, Q9, and Q10 Implementation, Rev. 2 (December 2011).

11. ISPE Guide Series, Product Quality Lifecycle Implementation (PQLI) from Concept to Continual Improvement,

12. J. Lepore and R. Nosal, R. "Industry Perspective: Value Proposition for Applications of Risk-Based Approaches," presented at ISPE Brussels Conference (2011).

13. C.J. Potter, Jrnl. of Pharma. Innov. 1:4–23 (2009).

14. EFPIA, (Publications/Science and Technical Affairs.)


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here